Eurofins Genomics launch “next generation DNA synthesis service”
Eurofins Genomics, an arm of the Eurofins Scientific laboratory group which specializes in genomic analysis, is releasing a “next generation” DNA synthesis service.
According to the group, the service is “designed to supply small quantities of high-quality oligos for use in molecular biology and synthetic biology, among other applications.”
Don’t be alarmed if that sentence makes no sense to you – the thrust of it is this: with current synthesis methods, scientists routinely end up paying for more than they need. Eurofins have figured out how to change this, so that their clients only pay for what they require.
Eurofins Scientific is up 31% in the last 12 months
Source: Yahoo Finance
Martin Kunz, the president of Eurofins Genomics US, made the following statement:
"By completely reimagining the synthesis process, including applying tenants of aerospace engineering, we have created a new platform that will help users accelerate their science while ensuring the quality and reliability of their results," said Martin Kunz, President, Eurofins Genomics US. "We have been very encouraged by feedback about our next-generation synthesis technology from customers in our beta program and are pleased to expand its availability to more scientists in the U.S."
The extent to which the new service resonates with Eurofins’ clients is yet to be seen – but it should be an attractive proposition. In effect, it allows scientists to perform more experiments for the same budget.
The company certainly seem to expect it to be popular, having expanded the operational hours for its service labs. If you want some DNA synthesized now, Eurofins is basically open 24 hours a day, seven days a week.
Dominion holds Eurofins Scientific in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.